CRNX

Crinetics Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 1/10
  • Momentum↑ 7/10
Crinetics Pharmaceuticals sales and earnings growth
CRNX Growth
Low
  • Revenue Y/Y↑ 47.74%
  • EPS Y/Y↓ -21.83%
  • FCF Y/Y↓ -73.18%
Crinetics Pharmaceuticals gross and profit margin trends
CRNX Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -27563.30%
  • ROIC↓ -36.00%
Crinetics Pharmaceuticals net debt vs free cash flow
CRNX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Crinetics Pharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗